{"name":"Genentech, Inc.","slug":"genentech-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":22,"colorKey":"oncology","drugs":[{"name":"ZN-A-1041 Formulation 1","genericName":"ZN-A-1041 Formulation 1","slug":"zn-a-1041-formulation-1","indication":"Other","status":"phase_1"},{"name":"GDC-0994","genericName":"GDC-0994","slug":"gdc-0994","indication":"Other","status":"phase_1"},{"name":"GDC-1971","genericName":"GDC-1971","slug":"gdc-1971","indication":"Other","status":"phase_1"},{"name":"KPL-716","genericName":"KPL-716","slug":"kpl-716","indication":"Other","status":"phase_2"},{"name":"Anti-inflammatory drugs","genericName":"Anti-inflammatory drugs","slug":"anti-inflammatory-drugs","indication":"Other","status":"phase_3"},{"name":"Cathflo Activase (Alteplase)","genericName":"Cathflo Activase (Alteplase)","slug":"cathflo-activase-alteplase","indication":"Restoration of function to central venous catheters occluded by thrombus","status":"marketed"},{"name":"First-Line Chemotherapy Agents","genericName":"First-Line Chemotherapy Agents","slug":"first-line-chemotherapy-agents","indication":"Other","status":"phase_2"},{"name":"GDC-0032 Phase III Tablet","genericName":"GDC-0032 Phase III Tablet","slug":"gdc-0032-phase-iii-tablet","indication":"Other","status":"phase_1"},{"name":"GDC-0068","genericName":"GDC-0068","slug":"gdc-0068","indication":"Other","status":"phase_1"},{"name":"GDC-0084","genericName":"GDC-0084","slug":"gdc-0084","indication":"Other","status":"phase_2"},{"name":"GDC-0134 F16 Formulation","genericName":"GDC-0134 F16 Formulation","slug":"gdc-0134-f16-formulation","indication":"Other","status":"phase_1"},{"name":"GDC-0919","genericName":"GDC-0919","slug":"gdc-0919","indication":"Other","status":"phase_1"},{"name":"GDC-4198","genericName":"GDC-4198","slug":"gdc-4198","indication":"Other","status":"phase_1"},{"name":"GDC-6599","genericName":"GDC-6599","slug":"gdc-6599","indication":"Other","status":"phase_2"},{"name":"GDC-9545 Capsule, Fasted: Treatment B","genericName":"GDC-9545 Capsule, Fasted: Treatment B","slug":"gdc-9545-capsule-fasted-treatment-b","indication":"Other","status":"phase_1"},{"name":"H1 antihistamines","genericName":"H1 antihistamines","slug":"h1-antihistamines","indication":"Allergic rhinitis","status":"phase_2"},{"name":"MFGR1877S","genericName":"MFGR1877S","slug":"mfgr1877s","indication":"Other","status":"phase_1"},{"name":"MHAB5553A","genericName":"MHAB5553A","slug":"mhab5553a","indication":"Other","status":"phase_1"},{"name":"Methyloprednisolone","genericName":"Methyloprednisolone","slug":"methyloprednisolone","indication":"Other","status":"phase_3"},{"name":"Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf","genericName":"Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf","slug":"pertuzumab-trastuzumab-and-hyaluronidase-zzxf","indication":"Other","status":"marketed"},{"name":"Prototype capsule GDC-0134","genericName":"Prototype capsule GDC-0134","slug":"prototype-capsule-gdc-0134","indication":"Other","status":"phase_1"},{"name":"oseltamivir [Tamiflu]","genericName":"oseltamivir [Tamiflu]","slug":"oseltamivir-tamiflu","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"respiratory","drugs":[{"name":"Onartuzumab (MetMab)","genericName":"Onartuzumab (MetMab)","slug":"onartuzumab-metmab","indication":"Metastatic non-small cell lung cancer (NSCLC) in combination with erlotinib","status":"phase_3"},{"name":"Tarceva (erlotinib HCl)","genericName":"Tarceva (erlotinib HCl)","slug":"tarceva-erlotinib-hcl","indication":"Non-small cell lung cancer, pancreatic cancer, and other types of cancer","status":"phase_3"},{"name":"erlotinib HCl","genericName":"erlotinib HCl","slug":"erlotinib-hcl","indication":"Non-small cell lung cancer (NSCLC), including EGFR-mutant and wild-type disease","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Tetanus Toxoid Adsorbed Vaccine","genericName":"Tetanus Toxoid Adsorbed Vaccine","slug":"tetanus-toxoid-adsorbed-vaccine","indication":"Active immunization against tetanus","status":"marketed"},{"name":"Raptiva (efalizumab)","genericName":"Raptiva (efalizumab)","slug":"raptiva-efalizumab","indication":"Moderate to severe plaque psoriasis","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Analgesic/antipyretic and antihistamine drugs","genericName":"Analgesic/antipyretic and antihistamine drugs","slug":"analgesic-antipyretic-and-antihistamine-drugs","indication":"Pain and fever with concurrent allergic symptoms","status":"phase_3"},{"name":"Dexamethasone Mouth Rinse","genericName":"Dexamethasone Mouth Rinse","slug":"dexamethasone-mouth-rinse","indication":"Oral inflammation and ulceration (aphthous ulcers, oral mucositis)","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"Asthma therapies","genericName":"Asthma therapies","slug":"asthma-therapies","indication":"Moderate to severe allergic asthma","status":"marketed"},{"name":"long-acting beta-agonists","genericName":"long-acting beta-agonists","slug":"long-acting-beta-agonists","indication":"Asthma maintenance therapy","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"Ocrelizumab Dose 1","genericName":"Ocrelizumab Dose 1","slug":"ocrelizumab-dose-1","indication":"Relapsing-remitting multiple sclerosis","status":"phase_3"},{"name":"Ocrelizumab Dose 2 and Dose 3","genericName":"Ocrelizumab Dose 2 and Dose 3","slug":"ocrelizumab-dose-2-and-dose-3","indication":"Relapsing forms of multiple sclerosis","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"rare","drugs":[{"name":"rhuFab V2 (ranibizumab)","genericName":"rhuFab V2 (ranibizumab)","slug":"rhufab-v2-ranibizumab","indication":"Neovascular (wet) age-related macular degeneration","status":"phase_3"}]}],"pipeline":[{"name":"ZN-A-1041 Formulation 1","genericName":"ZN-A-1041 Formulation 1","slug":"zn-a-1041-formulation-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GDC-0994","genericName":"GDC-0994","slug":"gdc-0994","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GDC-1971","genericName":"GDC-1971","slug":"gdc-1971","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"KPL-716","genericName":"KPL-716","slug":"kpl-716","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tetanus Toxoid Adsorbed Vaccine","genericName":"Tetanus Toxoid Adsorbed Vaccine","slug":"tetanus-toxoid-adsorbed-vaccine","phase":"marketed","mechanism":"Tetanus toxoid adsorbed vaccine stimulates the immune system to produce antibodies against tetanus toxin, providing active immunity against tetanus infection.","indications":["Active immunization against tetanus","Tetanus prophylaxis and booster immunization"],"catalyst":""},{"name":"Analgesic/antipyretic and antihistamine drugs","genericName":"Analgesic/antipyretic and antihistamine drugs","slug":"analgesic-antipyretic-and-antihistamine-drugs","phase":"phase_3","mechanism":"This is a combination drug class that reduces pain and fever through analgesic/antipyretic action while simultaneously blocking histamine receptors to reduce allergic responses.","indications":["Pain and fever with concurrent allergic symptoms","Cold and flu symptoms with allergy component"],"catalyst":""},{"name":"Anti-inflammatory drugs","genericName":"Anti-inflammatory drugs","slug":"anti-inflammatory-drugs","phase":"phase_3","mechanism":"Anti-inflammatory drugs reduce inflammation by inhibiting inflammatory pathways and mediators in the body.","indications":[],"catalyst":""},{"name":"Asthma therapies","genericName":"Asthma therapies","slug":"asthma-therapies","phase":"marketed","mechanism":"Asthma therapies from Genentech include multiple marketed drugs that work through different mechanisms to reduce airway inflammation and improve lung function in asthma patients.","indications":["Moderate to severe allergic asthma","Moderate to severe eosinophilic asthma","Moderate to severe atopic dermatitis with asthma"],"catalyst":""},{"name":"Cathflo Activase (Alteplase)","genericName":"Cathflo Activase (Alteplase)","slug":"cathflo-activase-alteplase","phase":"marketed","mechanism":"Alteplase is a tissue plasminogen activator (tPA) that converts plasminogen to plasmin, which breaks down fibrin clots.","indications":["Restoration of function to central venous catheters occluded by thrombus"],"catalyst":""},{"name":"Dexamethasone Mouth Rinse","genericName":"Dexamethasone Mouth Rinse","slug":"dexamethasone-mouth-rinse","phase":"phase_3","mechanism":"Dexamethasone is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and reducing production of pro-inflammatory cytokines.","indications":["Oral inflammation and ulceration (aphthous ulcers, oral mucositis)","Post-operative oral pain and swelling"],"catalyst":""},{"name":"First-Line Chemotherapy Agents","genericName":"First-Line Chemotherapy Agents","slug":"first-line-chemotherapy-agents","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GDC-0032 Phase III Tablet","genericName":"GDC-0032 Phase III Tablet","slug":"gdc-0032-phase-iii-tablet","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GDC-0068","genericName":"GDC-0068","slug":"gdc-0068","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GDC-0084","genericName":"GDC-0084","slug":"gdc-0084","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GDC-0134 F16 Formulation","genericName":"GDC-0134 F16 Formulation","slug":"gdc-0134-f16-formulation","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GDC-0919","genericName":"GDC-0919","slug":"gdc-0919","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GDC-4198","genericName":"GDC-4198","slug":"gdc-4198","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GDC-6599","genericName":"GDC-6599","slug":"gdc-6599","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GDC-9545 Capsule, Fasted: Treatment B","genericName":"GDC-9545 Capsule, Fasted: Treatment B","slug":"gdc-9545-capsule-fasted-treatment-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"H1 antihistamines","genericName":"H1 antihistamines","slug":"h1-antihistamines","phase":"phase_2","mechanism":"Blocks H1 histamine receptors","indications":["Allergic rhinitis","Urticaria","Anaphylaxis"],"catalyst":""},{"name":"MFGR1877S","genericName":"MFGR1877S","slug":"mfgr1877s","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MHAB5553A","genericName":"MHAB5553A","slug":"mhab5553a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Methyloprednisolone","genericName":"Methyloprednisolone","slug":"methyloprednisolone","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ocrelizumab Dose 1","genericName":"Ocrelizumab Dose 1","slug":"ocrelizumab-dose-1","phase":"phase_3","mechanism":"Ocrelizumab is a monoclonal antibody that depletes B cells by binding to CD20, reducing autoimmune-mediated inflammation.","indications":["Relapsing-remitting multiple sclerosis","Primary progressive multiple sclerosis"],"catalyst":""},{"name":"Ocrelizumab Dose 2 and Dose 3","genericName":"Ocrelizumab Dose 2 and Dose 3","slug":"ocrelizumab-dose-2-and-dose-3","phase":"phase_3","mechanism":"Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells.","indications":["Relapsing forms of multiple sclerosis","Primary progressive multiple sclerosis"],"catalyst":""},{"name":"Onartuzumab (MetMab)","genericName":"Onartuzumab (MetMab)","slug":"onartuzumab-metmab","phase":"phase_3","mechanism":"Onartuzumab is a monoclonal antibody that blocks hepatocyte growth factor (HGF) binding to the MET receptor, inhibiting MET-driven tumor growth and survival signaling.","indications":["Metastatic non-small cell lung cancer (NSCLC) in combination with erlotinib","Gastric cancer"],"catalyst":""},{"name":"Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf","genericName":"Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf","slug":"pertuzumab-trastuzumab-and-hyaluronidase-zzxf","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Prototype capsule GDC-0134","genericName":"Prototype capsule GDC-0134","slug":"prototype-capsule-gdc-0134","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Raptiva (efalizumab)","genericName":"Raptiva (efalizumab)","slug":"raptiva-efalizumab","phase":"marketed","mechanism":"Efalizumab blocks the CD11a subunit of lymphocyte function-associated antigen-1 (LFA-1), preventing T-cell activation and migration to the skin.","indications":["Moderate to severe plaque psoriasis"],"catalyst":""},{"name":"Tarceva (erlotinib HCl)","genericName":"Tarceva (erlotinib HCl)","slug":"tarceva-erlotinib-hcl","phase":"phase_3","mechanism":"Tarceva (erlotinib HCl) works by inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase.","indications":["Non-small cell lung cancer, pancreatic cancer, and other types of cancer","Locally advanced or metastatic non-small cell lung cancer"],"catalyst":""},{"name":"erlotinib HCl","genericName":"erlotinib HCl","slug":"erlotinib-hcl","phase":"phase_3","mechanism":"Erlotinib is a small-molecule tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR), preventing cancer cell proliferation and survival.","indications":["Non-small cell lung cancer (NSCLC), including EGFR-mutant and wild-type disease","Pancreatic cancer (metastatic, in combination with gemcitabine)"],"catalyst":""},{"name":"long-acting beta-agonists","genericName":"long-acting beta-agonists","slug":"long-acting-beta-agonists","phase":"phase_3","mechanism":"Long-acting beta-agonists bind to beta-2 adrenergic receptors on airway smooth muscle to cause sustained bronchodilation and improve airflow.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"oseltamivir [Tamiflu]","genericName":"oseltamivir [Tamiflu]","slug":"oseltamivir-tamiflu","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"rhuFab V2 (ranibizumab)","genericName":"rhuFab V2 (ranibizumab)","slug":"rhufab-v2-ranibizumab","phase":"phase_3","mechanism":"Ranibizumab is a recombinant humanized monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A).","indications":["Neovascular (wet) age-related macular degeneration","Macular edema following retinal vein occlusion","Diabetic macular edema"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxPTWpXc3VzY3BHVkgtSzBYbE4zc2Rkenc4ZGNYUUZCenVDaEVXdGtYT1pEVWlsWjNmQnplMjNPQjdsaVRhOFdQUDN1eUdUTFQwZUxfOUIwa2NZdFJhZk5lQXZ0ZWpmQzkwY3lLb1dtSnQ2dGlWamJ2NTFhckFreFZNbmtyLXJ2T3lPeG0yMENQOFgxdEhobklMU2VHOVBLYUNyX01iVjRyOVdRZTM2WDB6MncwUk96aUM2TElVRmVDSWFpaTBIU1pXQWJWNUJCcXlsTHBwYmJXdUNDYVFPT09TeVBEaW1HZ0xqMG1MdlgxcF9YTVBRVEIyR3d3anRnTUptcGhsQktRazlzNk9HTmtTV2ZNMGNxOEw3QTR6QThFbDZUazBOekJlRlRmV3Z0b2h4ckdnYnlqMDFvU25rVVdRV1ZTaTFJVl9aZFdzOUEyM3M?oc=5","date":"2026-04-08","type":"pipeline","source":"Barchart.com","summary":"COPD Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Genentech, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Sanofi, MedImmune, EpiEndo Pharma, Tetherex Pharma, AstraZene","headline":"COPD Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Genentech, GlaxoSmithKline, Verona Pharma,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxObDJySGI3NU1uenJPOW1RVzZCWmc0UjRPUkV3b1lOajhiQ25JQUhZVDdpU1Z6QUd3RTA2QjdYbXlDMjk1V05admtCUTY5TDVfZDhOYzlPN3pkd3JORDJsM3NVYlZQcGkzaHFITmhVWmdnS1RRNy0xYXdiZUVTNFJ6alhyMmNINmhrUi1qS2ZncDdsSHRTc3VTQnhONTdxdHFYS3NZMEt0bnQtTllvQ2JhVl9LSmJDWlA2M2pETGJtSnZZaHkxWjdnUmNCZjVlUDZvNk1ramRid0piOUpfWlRGdjZIMA?oc=5","date":"2026-01-20","type":"pipeline","source":"reuters.com","summary":"Roche's Genentech more than doubles investment in North Carolina facility to about $2 billion - reuters.com","headline":"Roche's Genentech more than doubles investment in North Carolina facility to about $2 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPQW9BZGQzcUR3SkNYcENzMEJDUURUWWRSQ2g0Q19tYzJfVlN6R0gzVlVIVkhUOGpHWW5zOW1HWWlJbWxHNXplQTRodTVlaWhGMklDSGVGMzFGbk5ZblRrX1djV2NZVHY5QnB1ZGtQTGtkTTU1VXRIR3JLSE43dnozeHdVbmY0a3ZCcHFJZjVqdmdVdFVlUV9xN3Y3RmY4RTUz?oc=5","date":"2026-01-06","type":"deal","source":"The Pharma Letter","summary":"Structure Therapeutics signs patent deal with Genentech - The Pharma Letter","headline":"Structure Therapeutics signs patent deal with Genentech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQRVV5V0VOWVY3OVNtaVl0eVV6ZTdyRXNsVVI2eEc5NU1KOHJXem1JTFAySklqQ3gyeWRtZnBaVXJYeDQ5UDZlejFZVG1rYlFvangyeW4xVEcwLURxLXF1ejlwOGNJS1o0WnhEd3BJekdrVkpTM1pzSDVYbkszbzFWMC1MMmxBMWtzVDcwM3JMcHBGN0xpNG1vcVRId2FmYzh0cVE?oc=5","date":"2025-10-01","type":"pipeline","source":"The Business Journals","summary":"How a small Bay Area drug company landed a potential $3.5 billion acquisition despite pharma funding drought - The Business Journals","headline":"How a small Bay Area drug company landed a potential $3.5 billion acquisition despite pharma funding drought","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOYTBfRC1ncmV1clN2QlJuZTNmeVJfUW1ORTExZk9hd0FEUlNRV2dyZ3IycmtPTmZIRTFwWnZjZFNibFQwU2xONFljZy0xd0oxQ201Y1RwVlpMelNyNU9pVTJMclU4NEZRbDU4dm56RHU5alBHUGxtYmsxWnRUYUNYdzRRYzFMVnFuSW9mX2dleGJ1b2tPT0ZwZ1g3SVdobEk?oc=5","date":"2025-09-22","type":"deal","source":"finance.yahoo.com","summary":"Starpharma Announces a Collaboration and License Agreement with Genentech - finance.yahoo.com","headline":"Starpharma Announces a Collaboration and License Agreement with Genentech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNbGtpWkl2LVNVcU1CeVdVbXloSzh4WnpQa2dYajcwd2puYU91R1kxaXRpbnBSSUsyWVlWdkp2V0ZxaEh2VHZaNmpDaEpyWTNSTDg2UFVNVVFpT2VkMUR6SW5Vdmt6cUZuSzVROHNGcnc4SjlhMkNsb3FWaXNlVWxwcVYwVHM5cXA2bno0dEQtZw?oc=5","date":"2025-09-22","type":"deal","source":"BioWorld News","summary":"Genentech $569M deal lifts Starpharma stock 73% - BioWorld News","headline":"Genentech $569M deal lifts Starpharma stock 73%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQWWpXUWhZamhUOWhCU2tNaU9VOTJha2N1SFNhVGh5YnFERnUwMEE3MS03RVZacEI3eUd0cFNRcVdOaWJNUGNVZmZVOEVFRWFTbmdWNnZQejQxZzNtTldaQVI0UVNlcFFqWDUtZEs0eXQtaF9kdFJCaE9lRUJncUw2ckNWem5WYkMwUDNOLURFUmRfN0hCY2ZNUkN6RkJDTW85ekNpMDBObzN5TEh0N2c?oc=5","date":"2025-09-18","type":"pipeline","source":"Fierce Pharma","summary":"Genentech names next marketing chief as Erica Taylor takes on new role at Roche - Fierce Pharma","headline":"Genentech names next marketing chief as Erica Taylor takes on new role at Roche","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQQzI2TDlncV90eW5CWVM0NWR0Z3c0RUp4UEN0M1VGNjBXWlFtazdKRDVDVU1RWGlIa1l4V3dJWlB1OGV2T1FBUW9mTVN1QW0zbG1MWDZzOHQwRlBvZUl5VkhEYjNJdG1meURPYm1HejdIM0paS2FtcTdqLUg2dG9sb2NrazV2M0RBQTVLWko5Y0hwem5RcUJOatIBVkFVX3lxTE8yZGhBYkpUUjhBZzliMEY3ZWJrN291QzNlRWMtdC1iOUtFYm5kR2ZmRGYwLURjOEYwRS1wcHJyajFMM002a013Snd5WjB0VlExcTIxZDNn?oc=5","date":"2025-06-06","type":"deal","source":"Law360","summary":"Genentech Wants $18M Novartis Award Over Licenses OK'd - Law360","headline":"Genentech Wants $18M Novartis Award Over Licenses OK'd - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQYVM0eE1NTHVhV19XdHphRE1vUU45a0lPNWRZc1pWeFVEcnEtODRsRWY1b0xUUmpzOXlrdFhxblU3bndoVERZMnhSNW5NRURaSE81NWN2UGg5dy1fYy00S2U0R3FaNzdOd2FIT1lQMzZZajlfbUcxa2FJUXdZWXpGMEZ2bDZJc1o3VHUzWHV2djAwS2JlSXJkTg?oc=5","date":"2025-05-23","type":"pipeline","source":"Pharmaceutical Technology","summary":"Genentech to onshore US manufacturing amid rising drug pricing tensions - Pharmaceutical Technology","headline":"Genentech to onshore US manufacturing amid rising drug pricing tensions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPQm5jR1V0UTJ3bm5YaVJJNzNnNXBWUmhlRDVjaFl2TFA0ckF2N0pfY3hrdDhFZ2U1WTNvcVZBUVVXaTk5TkVSbUstZ2tnVDNPbUtlYkhOdVZGYUhfdVgxMFIyVEtybzZjOGNXc0p3NVpOaHZrMm5QaHBwcGRkaTYxVm5ZUkUxWktKOWVYMGIzaDJ5dnk1eUFESF9xaHUxc0FkWkgxd1UyZWMyOXlhVEpvOXpndlFYN1VT?oc=5","date":"2025-05-13","type":"pipeline","source":"PharmTech.com","summary":"Genentech and Roche Expand US Footprint with New North Carolina Manufacturing Facility - PharmTech.com","headline":"Genentech and Roche Expand US Footprint with New North Carolina Manufacturing Facility","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPV19UVzgwZjk0WEIxZHJCT0hlVUtGYVhpMnZkR19RRXpHR0F2cnhJeTNLV3JMU0k5TE9maEdpZWZpMmNGVDA3M3hxRU5WQkN5aFYyNG92a2QyLXJHYnQwd3hwLVBJekg1WjZWQVpXeGNsR2JJOGFWaHBRdzFERFRXRDN4dnVneEtxNk1pTllQZDZyV3dHU1JYYw?oc=5","date":"2025-05-13","type":"pipeline","source":"carolinajournal.com","summary":"Pharmaceutical company to build manufacturing facility in NC - carolinajournal.com","headline":"Pharmaceutical company to build manufacturing facility in NC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPektPdFIzb2FYcUpnVC1UQV9MVE1wQkpwUGFmbXFWOHNWTnNmeGxodnc3RHJrNm1UajA4S1FfeXpPc0FhWmVMVXRlVmxCVlBkdmpXZHM1SERpSU1iNkxqSnhwbnRiQ3BhZE56SU1vX1gyRmtDUURxOU5zZFF4dHlhTzY2MDNRamh2WmsyeUlyMVFJMVpISHpLSjhKdw?oc=5","date":"2025-05-11","type":"pipeline","source":"WRAL","summary":"Biotech company Genentech to add 420 jobs in Holly Springs - WRAL","headline":"Biotech company Genentech to add 420 jobs in Holly Springs","sentiment":"neutral"}],"patents":[],"drugCount":34,"phaseCounts":{"phase_1":12,"phase_2":5,"marketed":6,"phase_3":11},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}